Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Ultragenyx Pharmaceutical Inc (RARE)  
$42.75 0.45 (1.04%) as of 4:30 Fri 5/3


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 82,110,000
Market Cap: 3.51(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $31.73 - $53.69
Level I Sector: Consumer Discretionary
Level II Sector: Leisure
Level III Sector: Restaurants

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ COMPOSITE
    NASDAQ INDUSTRIAL     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 69,133 99,133 200,384 249,340
Total Sell Value $3,373,178 $4,809,278 $8,291,909 $10,478,837
Total People Sold 8 8 9 12
Total Sell Transactions 10 11 20 34
End Date 2024-02-04 2023-11-03 2023-05-05 2022-05-05

   
Records found: 628
  Page 8 of 26  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Harris Erik EVP & Chief Commercial Officer   •       –      –    2021-03-01 4 AS $138.17 $341,280 D/D (2,470) 28,520 -36%     
   Harris Erik EVP & Chief Commercial Officer   •       –      –    2021-03-01 4 A $0.00 $0 D/D 10,136 30,990     -
   Huang Dennis Karl EVP & Chief Tech Ops Officer   •       –      –    2021-03-01 4 S $138.18 $587,956 D/D (4,255) 40,761 36%     
   Huang Dennis Karl EVP & Chief Tech Ops Officer   •       –      –    2021-03-01 4 A $0.00 $0 D/D 10,136 44,835     -
   Pinion John Richard See Remarks   •       –      –    2021-03-01 4 S $138.17 $856,378 D/D (6,198) 50,237 36%     
   Pinion John Richard See Remarks   •       –      –    2021-03-01 4 A $0.00 $0 D/D 10,136 56,435     -
   Aliski William Director   –       •      –    2021-02-23 4 GD $0.00 $0 D/D 1,000 64,704     -
   Aliski William Director   –       •      –    2021-02-19 4 S $149.01 $1,117,575 D/D (7,500) 65,704 36%     
   Aliski William Director   –       •      –    2021-02-19 4 OE $97.85 $733,875 D/D 7,500 73,204     -
   Bedrosian Camille L EVP and Chief Medical Officer   •       –      –    2021-01-30 4 S $140.36 $314,827 D/D (2,243) 33,546 30%     
   Bedrosian Camille L EVP and Chief Medical Officer   •       –      –    2021-01-15 4 AS $139.18 $3,479,500 D/D (25,000) 35,789 -25%     
   Bedrosian Camille L EVP and Chief Medical Officer   •       –      –    2021-01-15 4 OE $55.00 $1,375,000 D/D 25,000 60,789     -
   Huizenga Theodore Alan SVP, Controller and PAO   •       –      –    2021-01-07 4 AS $140.65 $562,600 D/D (4,000) 15,716 -23%     
   Huizenga Theodore Alan SVP, Controller and PAO   •       –      –    2021-01-07 4 OE $21.00 $84,000 D/D 4,000 20,436     -
   Kakkis Emil D President & CEO   •       •      –    2021-01-04 4 AS $136.90 $4,107,000 I/I (30,000) 2,329,741 -22%     
   Kakkis Emil D President & CEO   •       •      –    2020-11-02 4 AS $96.82 $2,904,600 I/I (30,000) 2,359,741 35%     
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-10-30 4 AS $100.12 $991,488 D/D (9,903) 24,061 26%     
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-10-30 4 OE $54.50 $539,714 D/D 9,903 33,871     -
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-10-28 4 AS $100.00 $9,700 D/D (97) 23,968 26%     
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-10-28 4 OE $54.50 $5,287 D/D 97 24,065     -
   Harris Erik EVP & Chief Commercial Officer   •       –      –    2020-10-14 4 S $88.00 $19,360 D/D (220) 23,370 -54%     
   Huizenga Theodore Alan SVP, Controller and PAO   •       –      –    2020-10-14 4 S $87.98 $12,845 D/D (146) 16,436 -54%     
   Pinion John Richard See Remarks   •       –      –    2020-10-14 4 S $88.00 $23,056 D/D (262) 46,299 -54%     
   Kakkis Emil D President & CEO   •       •      –    2020-10-14 4 D $92.69 $78,972 D/D (852) 610,189     -
   Bedrosian Camille L EVP and Chief Medical Officer   •       –      –    2020-10-14 4 S $88.00 $23,056 D/D (262) 35,789 -54%     
  628 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 26
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us